Four HDAC inhibitors, vorinostat, romidepsin, panobinostat and belinostat are now approved for the treatment of cutaneous T-cell lymphoma and other HDAC inhibitors are being clinically tested for other types of cancer. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.